SCHEMBL4637772

SCHEMBL4637772

COCNC(=O)c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.51
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
MAPT P10636 3/20 0.41
KDR P35968 1/20 0.40
AKR1C3 P42330 1/20 0.40
SORT1 Q99523 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TACR1 P25103 3/20 0.38
CFTR P13569 1/20 0.38
CYP19A1 P11511 1/20 0.38
SLC2A1 P11166 1/20 0.37
SLC2A3 P11169 1/20 0.37
SLC2A4 P14672 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637999 0.88 IDH1 (0.46) IDH1HCRTR1HCRTR2MAPTKDR
SCHEMBL4638629 0.84 HCRTR1 (0.44) IDH1HCRTR1HCRTR2KDRKDM4E
SCHEMBL4637742 0.84 ALDH1A1 (0.52) IDH1KDRSORT1ALDH1A1CYP19A1
SCHEMBL4637771 0.83 IDH1 (0.42) IDH1HCRTR1HCRTR2MAPTKDR
SCHEMBL4706658 0.83 IDH1 (0.62) IDH1HCRTR1HCRTR2MAPTSORT1
SCHEMBL4637833 0.83 CYP19A1 (0.59) IDH1MAPTKDRKDM4EALDH1A1
SCHEMBL4637730 0.81 MAPT (0.50) IDH1MAPTKDM4EMEN1ALDH1A1
SCHEMBL4638568 0.80 IDH1 (0.54) IDH1KDM4ESMN1; SMN2CFTRCYP19A1
SCHEMBL4707155 0.79 IDH1 (0.53) IDH1MAPTKDRALDH1A1SMN1; SMN2
SCHEMBL4638543 0.78 POLB (0.41) IDH1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 IDH1 4314/4885HCRTR1 159/4885HCRTR2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.